Slide 1: FY20 Results Presentation
This announcement was authorised by John Kelly, Managing Director Atomo Diagnostics Limited 701 – 703 Parramatta Road Leichhardt NSW 2040 Australia FY20 Results Presentation 31 August 2020 ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on the opportunity outlined in this presentation and no representation or warranty is made in information available as at the date of this presentation. The information in this presentation respect of such in
Slide 3: Introduction
INTRODUCTION Atomo Diagnostics Limited (ASX: AT1) is a medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market Headquartered in Australia with global operations, Atomo develops, manufactures and sells innovative patented devices that si
Slide 4: Key Highlights – Last Six Months
KEY HIGHLIGHTS – LAST SIX MONTHS • Partnership agreement signed in March 20 with NG Biotech SAS (France) for COVID-19 antibody RDT devices to be distributed in France. (NG Biotech has ordered 1.75m devices to date) • Successful IPO in April 20 raising $30 million • Company inclusion into ASX All Ord
Slide 5: Corporate
C O R P O R AT E KEY FINANCIAL DETAILS SHARE PRICE PERFORMANCE 0.6 ASX code AT1 0.5 Share price (28/08/20) $0.445 0.4 Shares on issue 561.1m 0.3 Options on issue 31.7m IPO @ 20c 0.2 Market cap $250m 0.1 Current cash (30/6/20) $27.1m 0 16-Apr 23-Apr 30-Apr 07-May 14-May 21-May 28-May 06-Aug 13-Aug 20
Slide 6: Patent Protected Solutions
PAT E N T P R O T E C T E D S O L U T I O N S Traditional ‘bits in a box’ kits Atomo’s fully integrated user-friendly solutions Standard lateral flow ‘bits in a box’ test kits Atomo has developed a range of The test process can be completed typically contain multiple components unique, integrated de
Slide 7: Two Business Models
TWO BUSINESS MODELS Marketing strategy maximises commercial opportunities to achieve scale across a broad range of applications FINISHED OEM PRODUCTS PLATFORM • Finished rapid test products • Assembled devices supplied to commercialised under Atomo's own brand diagnostic manufacturers, who or privat
Slide 8: Journey to Date
J O U R N E Y T O D AT E Atomo secures impact Atomo secures Atomo and Mylan Commencement of South African Atomo secures loan & follow on equity CE Mark for its partner for HIV sales to HIV assembly and Australian TGA from GHIF and a grant HIV Self-Test Self-Test distributors packing facility approva
Slide 9: COVID-19 Accelerates Demand for Atomo Test Devices
C O V I D - 1 9 A C C E L E R AT E S D E M A N D F O R AT O M O T E S T D E V I C E S COVID-19 COVID-19 Business Performance (FY20) • AtomoRapid test devices are in high demand to help • COVID-19 Sales Revenue - $3.4m address a significant increase in rapid testing requirements globally • COVID-19 U
Slide 10: COVID-19: Antibody Testing and Use Cases
COVID-19: ANTIBODY TESTING AND USE CASES With TGA approval received for its professional use test, Atomo is now progressing negotiations with potential applications in several areas: o Public health authorities – increased testing (including self- testing1) of populations to understand exposure and
Slide 11: Atomo Test: Accuracy & Ease of Use
AT O M O T E S T: A C C U R A C Y & E A S E O F U S E Public Hopital Bicêtre, France: COVID Study • Found that “Sensitivity and Specificity were 97.0% and 100% respectively, 15 days after the onset of symptoms.” Pasteur Institute, (French National Reference Laboratory): COVID Study • Found that 15 d
Slide 12: HIV Test Devices
HIV TEST DEVICES HIV Self-Test HIV Business Performance (FY20) • Atomo’s HIV self-test is the only HIV • HIV Sales Revenue - $1.2m self-test approved in Australia (TGA). Also approved in Europe (CE Mark) • HIV Units Sold - 226k and prequalified by the World Health Organisation (WHO) Drivers of Growt
Slide 13: Other OEM Products
OTHER OEM PRODUCTS OEM Contracts OEM Business Performance (FY20) • NG Biotech: (France) – supply • OEM Sales Revenue – $0.8m agreement covering pregnancy testing. Atomo tests are more • OEM Units Sold – 266k accurate early-stage than urine tests and more easily deployed in Accident & Emergency setti
Slide 14: Anticipated Progress During FY21
A N T I C I PAT E D P R O G E S S D U R I N G F Y 2 1 COVID North American deal with US Co. Access Bio • The Atomo / Access Bio CareStart COVID-19 rapid test to be submitted to FDA of Emergency Use AtomoRapid COVID-19 professional use test TGA Approval Authorization (EUA) as a Point of Care Test
Slide 15: Priorities Beyond FY21
PRIORITIES BEYOND FY21 Continued expansion of strategic commercialisation and distribution partnerships across key global markets and a clear focus on expansion of clinical test applications commercialised on Atomo devices Seek new global markets for COVID-19 and HIV as well as scaling up our OEM sa
Slide 16: Additional Applications for Atomo's Technology
A D D I T I O N A L A P P L I C AT I O N S F O R AT O M O ’ s T E C H N O L O G Y • Atomo intends to commercialise a number of additional AtomoRapid test products with a focus on the North American and European markets Commercialised existing lateral flow applications compatible with Atomo devices H
Slide 17: Extensive Product and Manufacturing IP & Knowhow
E X T E N S I V E P R O D U C T A N D M A N U FA C T U R I N G I P & K N O W H O W Extensive IP Portfolio: Atomo’s proprietary automated Atomo’s wholly owned HIV Self Several patent families granted or blister process operating: USA. Test Assembly facility in Cape pending (territories in red)* Town,
Slide 18: Underlying Profit & Loss
U N D E R LY I N G P R O F I T & L O S S FY20 FY19 Variance Annual Sales Revenue ($m) AUD ($m) ($m) (%) Revenue 5.37 0.54 895% Costs of Sales (2.17) (0.44) 390% Gross Profit 3.19 0.10 3217% Gross Margin 60% 18% Other Income 0.84 1.33 -36% Employee benefits expense (2.97) (2.10) 41% Foreign exchange
Slide 19: Balance Sheet
BALANCE SHEET FY20 FY19 AUD • Cash balance of $27.10 million as at 30 June 2020 ($m) ($m) Cash and cash equivalents 27.10 1.86 • During the year, the Company raised $46.05 million (before costs) in Trade and other receivables 3.49 0.58 new funds including: Inventories 1.21 0.79 - $16.05 million via
Slide 20: Investment Highlights
INVESTMENT HIGHLIGHTS Proven technology - the world’s first fully integrated, blood-based rapid test devices Market leader in fully integrated rapid tests with over 2 million devices sold globally Atomo’s award winning devices deliver ‘best in class’ rapid tests for HIV, COVID-19, and a range of oth
Slide 21: John Kelly, Managing Director
John Kelly Managing Director john.kelly@atomodiagnostics.com +61 401 922 279 atomodiagnostics.com
Slide 22: Appendix A – Profit & Loss Reconciliation
APPENDIX A – Profit & Loss Reconciliation FY20 FY19 • The underlying EBITDA of -$2.38m presented reconciles to the statutory AUD loss for the year of $9.22 million by removing the impact of IPO costs, ($m) ($m) depreciation and amortisation and financing costs which were Statutory loss for the year